PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Price Stock Quantity  
USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PD184352 (CI-1040) Chemical Structure

PD184352 (CI-1040) Chemical Structure
Molecular Weight: 478.67

Validation & Quality Control

Cited by 43 publications:

12 customer reviews :

Quality Control & MSDS

Related Compound Libraries

PD184352 (CI-1040) is available in the following compound libraries:

MEK Inhibitors with Unique Features

Product Information

  • Compare MEK Inhibitors
    Compare MEK Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Targets MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
IC50 17 nM 17 nM
In vitro CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
H9MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXn5RnhIUUN3ME2wMlAzOjd4IN88US=>NVr1TopYW0GQR1XS
CHP-212NGr0OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml64TWM2OD1yLkCyPFg2KM7:TR?=MXfTRW5ITVJ?
EoL-1-cellM1XJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTBwMESxOVIh|ryPNIPNbG9USU6JRWK=
DU-4475NFfYVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7mTWM2OD1yLkC3OVk6KM7:TR?=M4XUXHNCVkeHUh?=
MMAC-SFMlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLnTWM2OD1yLkGwPVc1KM7:TR?=M{WydHNCVkeHUh?=
AGSNFrKWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrmN|ZWUUN3ME2wMlEyPzF|IN88US=>NEHo[YVUSU6JRWK=
M14MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3qN|JKSzVyPUCuNVU1PjhizszNNWjBXGQ3W0GQR1XS
CP50-MEL-BMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\CPGlEPTB;MD6xO|I2PCEQvF2=MmLjV2FPT0WU
C32NGCw[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXS2fHBUUUN3ME2wMlE6ODd{IN88US=>MXnTRW5ITVJ?
KMOE-2NVTZ[nl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDhVIxzUUN3ME2wMlE6Pzl3IN88US=>M4XZd3NCVkeHUh?=
A101DNHjIS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjQTWM2OD1yLkKxOEDPxE1?NXrzPGw5W0GQR1XS
KM12M2XZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjRTWM2OD1yLkK0NFU4KM7:TR?=MkTSV2FPT0WU
HSC-4M2PKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHjTWM2OD1yLkK0N|k2KM7:TR?=Mlz5V2FPT0WU
NOMO-1NHzjO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorMTWM2OD1yLkK1O|QzKM7:TR?=NYryUlVbW0GQR1XS
MZ7-melNG\2cHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nNb2lEPTB;MD6yOlM1KM7:TR?=NHTyVo5USU6JRWK=
ACNMo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HHTGlEPTB;MD6yOlc{PyEQvF2=NVW4WGl3W0GQR1XS
MEL-HOMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDrZZlKSzVyPUCuNlc3PTJizszNMVTTRW5ITVJ?
BHT-101MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWGyWWJVUUN3ME2wMlI5PjB4IN88US=>NVO1VYR7W0GQR1XS
SK-MEL-28M1XNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1m5bmlEPTB;MD6zNFQxQSEQvF2=MYDTRW5ITVJ?
KG-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzrT2pKSzVyPUCuN|A3PjhizszNNYruSW1mW0GQR1XS
COLO-679NVXhTm81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn76TWM2OD1yLkOyO|Ih|ryPMVnTRW5ITVJ?
SK-MEL-24NYPv[41YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXGTWM2OD1yLkOyPFE{KM7:TR?=NXO5RW1OW0GQR1XS
G-361MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7sbFFLUUN3ME2wMlM3Pzl3IN88US=>NH6xdWRUSU6JRWK=
KY821NXTJOZVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTBwM{e5NUDPxE1?MWTTRW5ITVJ?
KASUMI-1NVLzXFZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXkZow{UUN3ME2wMlM6QSEQvF2=NV2yN2lHW0GQR1XS
HL-60MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkO1TWM2OD1yLkSxNVA4KM7:TR?=NVfpNVhnW0GQR1XS
K5MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LOdGlEPTB;MD60N|EyPyEQvF2=MkjRV2FPT0WU
KU812NFnsUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTvTWM2OD1yLkS1Nlk6KM7:TR?=M2TJdnNCVkeHUh?=
SH-4MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkizTWM2OD1yLkS2NlU3KM7:TR?=Mm[3V2FPT0WU
HTC-C3M1jHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\kWVB3UUN3ME2wMlQ3PTNzIN88US=>M{LoUnNCVkeHUh?=
CP66-MELMlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPvTWM2OD1yLkS4PFA6KM7:TR?=M{GzT3NCVkeHUh?=
WM-115MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TESGlEPTB;MD60PVI2PyEQvF2=M2K5dXNCVkeHUh?=
A2780NF6zRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPkXop6UUN3ME2wMlQ6QDJ|IN88US=>Ml\wV2FPT0WU
P12-ICHIKAWANV3SbXI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDUZVlKSzVyPUCuOlEzOjFizszNNIPOTYhUSU6JRWK=
HMV-IIMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTBwNkS0OlUh|ryPMn;DV2FPT0WU
HT-144MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTqbYxtUUN3ME2wMlY1PjV5IN88US=>M2TWOnNCVkeHUh?=
LB2518-MELNVf6bG5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnq5TWM2OD1yLkexOlMzKM7:TR?=Mo\KV2FPT0WU
NCI-SNU-1Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELWWnhKSzVyPUCuO|U1OzNizszNMYHTRW5ITVJ?
C2BBe1Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzRVG9KSzVyPUCuPFExOjNizszNM2fTeXNCVkeHUh?=
PSN1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTBwOU[xPVYh|ryPMkGzV2FPT0WU
UACC-257M3nBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTBwOU[0O|Mh|ryPNF[2VpBUSU6JRWK=
RVH-421NIL2dGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUKxUpNGUUN3ME2wMlk4OThizszNMYXTRW5ITVJ?
GP5dM{CycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTBwOUizNFgh|ryPNVTmSpRmW0GQR1XS
TYK-nuMorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH73NllKSzVyPUGuNFMyPzJizszNMXLTRW5ITVJ?
SK-N-ASM4P2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\2VW9KSzVyPUGuNFc6PDdizszNMV;TRW5ITVJ?
SW620M3vHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHO2NY5KSzVyPUGuNVM2OzRizszNNGPMNnBUSU6JRWK=
HuP-T4M1n6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7VTZRvUUN3ME2xMlE5OzV7IN88US=>MlrPV2FPT0WU
A549MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Hq[GlEPTB;MT6xPVU4PiEQvF2=Mn7aV2FPT0WU
MewoM2PrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPNTWM2OD1zLkKwNlc3KM7:TR?=M4ThbHNCVkeHUh?=
ONS-76NXPrZmdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TJVWlEPTB;MT6yNlA1QSEQvF2=M4DiUHNCVkeHUh?=
SK-MEL-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TudGlEPTB;MT6yN|QyQSEQvF2=NXiye4hyW0GQR1XS
RCM-1NGXZXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\3NGlEPTB;MT6yOFA1PyEQvF2=NVnNXGNqW0GQR1XS
H-EMC-SSMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPXdZVUUUN3ME2xMlI6PjB6IN88US=>M1;2O3NCVkeHUh?=
NCI-H2291MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTFwM{K1N|Yh|ryPMkPhV2FPT0WU
SW1463NGLVT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkX1TWM2OD1zLkOzO|IyKM7:TR?=NULpeYhuW0GQR1XS
LS-411NMn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVy4fIFJUUN3ME2xMlQxPTF5IN88US=>NHfCV2RUSU6JRWK=
BV-173NGmwNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTFwNESwNVUh|ryPMoTVV2FPT0WU
LS-513M2CwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDpfVlKSzVyPUGuOFUyQTJizszNM1PvPXNCVkeHUh?=
LoVoMmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFW0T4FKSzVyPUGuOFY{QTlizszNNWTYfHJ{W0GQR1XS
HO-1-N-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFf5UodKSzVyPUGuOVE3OzRizszNNHfGWmlUSU6JRWK=
ML-2NHjPOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTFwNUK4Olgh|ryPM{fVfnNCVkeHUh?=
NCI-H1437MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLNTWM2OD1zLkW1Nlc2KM7:TR?=NWG1c|F5W0GQR1XS
SW1116MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{L2dWlEPTB;MT61OlM6QCEQvF2=MVzTRW5ITVJ?
A4-FukM{jjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTFwNUewOFUh|ryPM1PQWXNCVkeHUh?=
HD-MY-ZMojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUO4UokzUUN3ME2xMlU4Ozd4IN88US=>NV7LNI5[W0GQR1XS
SK-MEL-2NUf5boJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTFwNUe0OVkh|ryPMkXuV2FPT0WU
RT-112M4XaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPQR5A1UUN3ME2xMlU5QTV{IN88US=>MUDTRW5ITVJ?
COLO-829M3HZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHHTWM2OD1zLk[yNlMzKM7:TR?=M{S0fHNCVkeHUh?=
OVCAR-5M36zZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvERXZKSzVyPUGuO|c3QDdizszNNUPZZnc{W0GQR1XS
NB69MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zISmlEPTB;MT63PFQ3QSEQvF2=M{nqbXNCVkeHUh?=
NCI-H292MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTFwOE[2PVkh|ryPNFzzU5hUSU6JRWK=
LOXIMVIMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFWzOY1KSzVyPUGuPFk1OjdizszNNUHrTIlYW0GQR1XS
BPH-1NEDuTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PsZ2lEPTB;MT64PVU6OSEQvF2=NWrofmlPW0GQR1XS
A375Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYP4ZnFKUUN3ME2xMlg6PzF2IN88US=>NVTzV3o5W0GQR1XS
LCLC-97TM1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXz3Vm5VUUN3ME2xMlkzOjV4IN88US=>M4jOUXNCVkeHUh?=
RXF393M4DV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjFTWM2OD1zLkm3PFg4KM7:TR?=Mkf3V2FPT0WU
HCC70Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13ufmlEPTB;Mj6wNlQzPiEQvF2=NUL0bWNqW0GQR1XS
EM-2NWTBeWtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTJwMEexPVgh|ryPM{nne3NCVkeHUh?=
MZ2-MELNF7BO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nubmlEPTB;Mj6xNVEzPyEQvF2=M1jEV3NCVkeHUh?=
HNM1XWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TtdWlEPTB;Mj6xOlI4QCEQvF2=M3:wZnNCVkeHUh?=
A2058NFLaTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nOUmlEPTB;Mj6xPVI4QSEQvF2=NXjNXpNLW0GQR1XS
NB7NGWyRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\qe2lEPTB;Mj6zOFA5PiEQvF2=NWLkeHJUW0GQR1XS
DOKMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\SWWlEPTB;Mj6zOVc4OyEQvF2=NILnNJZUSU6JRWK=
CAL-27M4r6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nndGlEPTB;Mj6zPVI{PiEQvF2=MWjTRW5ITVJ?
BB65-RCCMmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LSRWlEPTB;Mj60NFY4PCEQvF2=NIjiTXhUSU6JRWK=
RDNVTseYVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;ZWmxWUUN3ME2yMlQ1PzJ|IN88US=>MXvTRW5ITVJ?
KNS-62NEjWXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHQc4xKSzVyPUKuOVEyPjRizszNNYnQW4hIW0GQR1XS
EW-13NIHGNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXNTWM2OD1{LkW2N|M6KM7:TR?=NXjpTVltW0GQR1XS
DBMn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjGWlNqUUN3ME2yMlU5Pzh6IN88US=>NGTT[41USU6JRWK=
HCC2218MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHe5bo9KSzVyPUKuOlQ4PzhizszNNF3USoJUSU6JRWK=
L-363Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTJwN{SzO{DPxE1?NV:xVY1kW0GQR1XS
CHL-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTJwOEC3PFUh|ryPNFHqR29USU6JRWK=
BFTC-905M{PuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3raVWlEPTB;Mj64NlU{KM7:TR?=MVnTRW5ITVJ?
HCE-TNGjFdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTJwOEOyOlQh|ryPMV;TRW5ITVJ?
COLO-792NEDzbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvITWM2OD1{Lki0NFI4KM7:TR?=MnjVV2FPT0WU
LB2241-RCCMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\je3NEUUN3ME2yMlg2QDl|IN88US=>NFu1VGNUSU6JRWK=
CAL-39M4jiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvpbGg2UUN3ME2yMlg6QTl7IN88US=>NHPNdG5USU6JRWK=
T-24NF3UTJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPWSnBKSzVyPUKuPVEyOTJizszNNXvVUoIzW0GQR1XS
NCI-H727NWOwToM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXpW5FKSzVyPUKuPVE4QTZizszNNXv3e3Z2W0GQR1XS
Ca9-22MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTJwOUeyOVUh|ryPM1T1ZXNCVkeHUh?=
MIA-PaCa-2MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3kTlhQUUN3ME2zMlAxPzhzIN88US=>MVzTRW5ITVJ?
HT-1080M{ey[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLPTWM2OD1|LkCxPVk4KM7:TR?=NIL3dVFUSU6JRWK=
D-423MGM4PldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkflTWM2OD1|LkC3O|U{KM7:TR?=MnHBV2FPT0WU
LAMA-84MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlOzTWM2OD1|LkGzOVgh|ryPMkHhV2FPT0WU
SW780MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInubXdKSzVyPUOuNVQzOjlizszNMYPTRW5ITVJ?
KU-19-19NFTqWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjFTWM2OD1|LkG3NFM1KM7:TR?=MYTTRW5ITVJ?
COLO-741NV6ySJgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\ES3NFUUN3ME2zMlE5Pjd|IN88US=>NUjTb2FzW0GQR1XS
HSC-3NX\CdplxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILLeW1KSzVyPUOuNlMyPTFizszNNXT0SYVIW0GQR1XS
SN12CM{j4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFexPZNKSzVyPUOuNlQ4ODFizszNMnTLV2FPT0WU
786-0NWHM[pVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGCwUoZKSzVyPUOuNlczPDNizszNM3zBXXNCVkeHUh?=
GAKMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TXSGlEPTB;Mz6zNlU3OSEQvF2=MnTUV2FPT0WU
PANC-03-27M2n6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3H6OmlEPTB;Mz6zOVA1PSEQvF2=MWHTRW5ITVJ?
CTB-1NX7ieJVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTNwNEewOFch|ryPM1;IPXNCVkeHUh?=
A427MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTNwNUm1OVYh|ryPMlHmV2FPT0WU
EGI-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3DTWM2OD1|Lk[wOVg{KM7:TR?=M4LrcHNCVkeHUh?=
U-2-OSNYrGSXJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTNwNkeyOVYh|ryPMVnTRW5ITVJ?
NCI-SNU-5MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUSzRpc3UUN3ME2zMlY4PzNizszNNVvuW|ZuW0GQR1XS
SK-LU-1NEi5NVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nXSGlEPTB;Mz62PFc6QCEQvF2=MUXTRW5ITVJ?
697M{X6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2O4R2lEPTB;Mz62PVYxOyEQvF2=NGTEb4ZUSU6JRWK=
HPAF-IIMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXH2UpRpUUN3ME2zMlc2PDlizszNM4Gzb3NCVkeHUh?=
NCI-H2087NVv2Zo9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\3VHNCUUN3ME2zMlg1Pjd{IN88US=>M1O5Z3NCVkeHUh?=
SK-MEL-3MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTZVlJNUUN3ME2zMlg2OTV2IN88US=>M{G0cnNCVkeHUh?=
CGTH-W-1MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nDWWlEPTB;Mz64OVczPSEQvF2=M{jacnNCVkeHUh?=
8505CNGLJdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3:0WGlEPTB;Mz65NFA4QCEQvF2=MV3TRW5ITVJ?
GAMGM4T3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTNNZVKSzVyPUSuNFI{PzdizszNNFXDV5pUSU6JRWK=
SW626M2\aeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TXUmlEPTB;ND6wOFQ5KM7:TR?=NU\XNW1mW0GQR1XS
CAL-62M1fLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTRwMEe0N{DPxE1?M1XoOXNCVkeHUh?=
MHH-PREB-1NV3NdJpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3YTWM2OD12LkGyNVEyKM7:TR?=NGS0UnlUSU6JRWK=
RPMI-7951NXLmS2RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTRwMkW1PFkh|ryPNVrReZFGW0GQR1XS
HOP-92M2jCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYj5WYx3UUN3ME20MlI2PjdizszNMXLTRW5ITVJ?
MDA-MB-231M2\h[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnabG1XUUN3ME20MlI6OjJ|IN88US=>MlTwV2FPT0WU
LAN-6NUPCRmtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonjTWM2OD12LkOxOlM4KM7:TR?=MV3TRW5ITVJ?
ALL-PONFf4b4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjwZ41kUUN3ME20MlM3OTV4IN88US=>M{\KWHNCVkeHUh?=
HHM{\Oe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;vfWlEPTB;ND60NVU6PyEQvF2=MnvxV2FPT0WU
IGROV-1M4\aUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HjSWlEPTB;ND60OVE4OSEQvF2=MVrTRW5ITVJ?
NCI-H358NFH0bZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnSNWFNUUN3ME20MlQ2Ozh3IN88US=>MYfTRW5ITVJ?
NB5NXTRe3lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvOTWM2OD12Lk[wN|Y6KM7:TR?=MoDKV2FPT0WU
NCI-H747MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrYcJJKSzVyPUSuOlg5ODdizszNNHjsbndUSU6JRWK=
NH-12MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLGXVRYUUN3ME20MlcyPjJ3IN88US=>MnPSV2FPT0WU
LB1047-RCCNXrJTI13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPETWM2OD12LkezPFE2KM7:TR?=M1\UO3NCVkeHUh?=
EFO-27M1y1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXvRZRKSzVyPUSuO|g3PjdizszNMXHTRW5ITVJ?
EPLC-272HNWDPWG9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHITWM2OD12Lkm5OlY6KM7:TR?=NFjFbldUSU6JRWK=
CAL-54MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELtSJdKSzVyPUWuNFI3QTVizszNNGjQRYFUSU6JRWK=
H4MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvHTWM2OD13LkC0NlU2KM7:TR?=NV[4cmtKW0GQR1XS
MOLT-13NGrXd2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3i4[mlEPTB;NT6wOlc4PiEQvF2=MkGwV2FPT0WU
CAL-33Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXX0TJhuUUN3ME21MlEzOzF5IN88US=>NYDIR5pPW0GQR1XS
23132-87NFzEdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTVwMU[4O|Ih|ryPMXfTRW5ITVJ?
UM-UC-3NU\ibWhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoC4TWM2OD13LkG4NFQ4KM7:TR?=MWTTRW5ITVJ?
HuH-7NF7TcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFiybm9KSzVyPUWuNlcyPDdizszNMkDLV2FPT0WU
BCPAPNGrnfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfrdJBKSzVyPUWuN|I6PjlizszNNGnvflFUSU6JRWK=
AsPC-1M4HtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DnRmlEPTB;NT6zOlc3OyEQvF2=NFjocWZUSU6JRWK=
NCI-H1155M13EdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37uXmlEPTB;NT60NFA2OSEQvF2=NUDveogxW0GQR1XS
GT3TKBMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYT4dXB2UUN3ME21MlQ3PTl6IN88US=>M3vRV3NCVkeHUh?=
HCC2998MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;ocpNKSzVyPUWuOFkyODlizszNMkHvV2FPT0WU
NUGC-3NIrSXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TvZmlEPTB;NT60PVMxOiEQvF2=M3nDdXNCVkeHUh?=
Hs-578-TM1LLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\iTWM2OD13LkWzO|k1KM7:TR?=Ml7MV2FPT0WU
FADUNV\ONXF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTVwNUW3NlYh|ryPMXPTRW5ITVJ?
NBsusSRM4r1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTVwNUexOVUh|ryPNE\OT|BUSU6JRWK=
ME-180MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIGy[I9KSzVyPUWuOVgxQTJizszNNYfCWZd2W0GQR1XS
SW1710MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3Rbol6UUN3ME21MlYyPjV2IN88US=>NGLXc|JUSU6JRWK=
HuP-T3MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jneWlEPTB;NT62NlAzQSEQvF2=M1;jUHNCVkeHUh?=
HOSNIfNb3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrnXJVvUUN3ME21MlYzQTJ|IN88US=>NIfLWWVUSU6JRWK=
PA-1M2frdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\wUI1ZUUN3ME21MlY1OjZ3IN88US=>NV33[3NlW0GQR1XS
LU-99AMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPRb5hKSzVyPUWuOlY1PTFizszNNFvYcVJUSU6JRWK=
RS4-11MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjWc3RKSzVyPUWuOlY4PzVizszNMoDJV2FPT0WU
TE-8NYLjWlN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\tVWlEPTB;NT62PFU{PyEQvF2=NF3Qe2xUSU6JRWK=
RERF-LC-MSNIjaeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojnTWM2OD13Lk[4PFA{KM7:TR?=MUXTRW5ITVJ?
MEL-JUSOMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTVwN{O3PEDPxE1?M3rHNHNCVkeHUh?=
SK-MES-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzCUYdmUUN3ME21Mlg{PTJ6IN88US=>Ml7IV2FPT0WU
D-263MGNEGxVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HGeGlEPTB;NT64PFM2OSEQvF2=M1PtcXNCVkeHUh?=
NB10M33iXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTVwOEm0OkDPxE1?M2\zWnNCVkeHUh?=
SK-HEP-1MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlu4TWM2OD13LkmzOFcyKM7:TR?=M3m1fXNCVkeHUh?=
HT-29M4HYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HOW2lEPTB;NT65PFEyQCEQvF2=M2\EfnNCVkeHUh?=
KYSE-140NUHPbGhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXVTWM2OD14LkCyNVgzKM7:TR?=MUfTRW5ITVJ?
NCI-H1666MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TjSWlEPTB;Nj6wPFQ3OSEQvF2=NXTXW3ZnW0GQR1XS
NCI-H1304M2HWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LIemlEPTB;Nj6xPVk1KM7:TR?=NEDQXnZUSU6JRWK=
RPMI-8866Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\ETWM2OD14LkKxN|E{KM7:TR?=NXrQOmJlW0GQR1XS
MV-4-11MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3W0b2lEPTB;Nj6yN|E6QSEQvF2=NVfNTWh7W0GQR1XS
A431M1rKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTZwMkSyPVYh|ryPNIr1cW1USU6JRWK=
PANC-10-05NGnWO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DoV2lEPTB;Nj6yPFM3OyEQvF2=NH3q[pBUSU6JRWK=
TK10M3HhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3qyPWlEPTB;Nj6zNlYxPCEQvF2=NULaUVRZW0GQR1XS
NCI-H1975NH7KR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHS1cZRKSzVyPU[uOFczOTVizszNNELJNmJUSU6JRWK=
A172MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTZwNEmxO|Yh|ryPMX;TRW5ITVJ?
D-566MGMmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHH2S5hKSzVyPU[uOVQ{ODNizszNM4DWe3NCVkeHUh?=
NCI-H2122NGPG[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk[xTWM2OD14Lk[xOVI5KM7:TR?=MVfTRW5ITVJ?
COR-L105NV\iV3lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLNfJdKSzVyPU[uOlUzPzVizszNMlPEV2FPT0WU
AN3-CANVO1OG0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTZwNki2OFEh|ryPM1u3b3NCVkeHUh?=
Calu-6NUXrZoc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3Ly[WlEPTB;Nj63PVY6QCEQvF2=NGe3cZhUSU6JRWK=
HCT-116MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;0PVZKSzVyPU[uPFEzPjRizszNNHi0RoNUSU6JRWK=
MHH-NB-11MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIK1UnlKSzVyPU[uPFUxODJizszNNH7KbW1USU6JRWK=
MFE-280M4OzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWH4fXR6UUN3ME22Mlg2QTh|IN88US=>MX;TRW5ITVJ?
SW1088NH;yOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NESwSGZKSzVyPU[uPVE6OTNizszNNVW2SGl3W0GQR1XS
SW48MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fqdGlEPTB;Nj65OFUyKM7:TR?=M{DaTHNCVkeHUh?=
HuCCT1NWL4Omx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTdwMEGwN|ch|ryPM3rUTXNCVkeHUh?=
ACHNNI\uV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vRN2lEPTB;Nz6wNlk1OyEQvF2=MmnFV2FPT0WU
8305CMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUn0T3NtUUN3ME23MlA6QTl3IN88US=>NEHNR4FUSU6JRWK=
DoTc2-4510M2SzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XQOWlEPTB;Nz6xNlE2KM7:TR?=M3jFWXNCVkeHUh?=
COR-L23M2Hqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Twb2lEPTB;Nz6yOFQzKM7:TR?=M2jHfHNCVkeHUh?=
SK-MEL-30M{LFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PYemlEPTB;Nz6yOVA5OyEQvF2=MVTTRW5ITVJ?
BE-13NUXFVpVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLxWm16UUN3ME23MlM{QDN2IN88US=>MV\TRW5ITVJ?
GR-STNF7BXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3iyR2lEPTB;Nz60NFE4PCEQvF2=NUTaWY9RW0GQR1XS
LU-135M2LHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYO1S3NEUUN3ME23MlU2QTN7IN88US=>MV7TRW5ITVJ?
U-266MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfiTWM2OD15LkW2Nlg3KM7:TR?=NWPoSoRmW0GQR1XS
NCI-H1355NFzENpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPFNGNKSzVyPUeuOVg3OzVizszNMX7TRW5ITVJ?
NB14NVjlUWd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\XRpRKSzVyPUeuOlY3PDJizszNNXnL[mV3W0GQR1XS
SCC-25MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTdwN{C5JO69VQ>?MnvrV2FPT0WU
COLO-678NV\ObpFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHZTWM2OD15LkexNFc3KM7:TR?=M3XWU3NCVkeHUh?=
TGBC1TKBMmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjTTWZKSzVyPUeuPFk{QThizszNNIHncFlUSU6JRWK=
IST-MEL1NH7INXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3Xxd2lEPTB;OD6wNFQxPiEQvF2=M2DQWHNCVkeHUh?=
ECC10NF71[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\tUHVKSzVyPUiuNFM{QTVizszNMmj4V2FPT0WU
EW-16MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jVfGlEPTB;OD6wPFQ1PSEQvF2=M4CyUHNCVkeHUh?=
DOHH-2NUfNSog5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWP1UZJmUUN3ME24MlIxODl3IN88US=>M164VnNCVkeHUh?=
NCI-H1581NHH2cXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRThwMk[zNlMh|ryPNWO3SWoxW0GQR1XS
TE-5MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRThwNEK0Nlkh|ryPMUPTRW5ITVJ?
CAKI-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHy5SXFKSzVyPUiuOVczOjJizszNMW\TRW5ITVJ?
A673NXuzd|RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRThwNkOyNFIh|ryPMWjTRW5ITVJ?
CAL-12TNFrpUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXP0XXpyUUN3ME24MlY2PzV|IN88US=>MljRV2FPT0WU
DBTRG-05MGNGX0TnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUL3e3RvUUN3ME24Mlc1QDV7IN88US=>NGP6THBUSU6JRWK=
SK-N-FIMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkmyTWM2OD16LkixN|c6KM7:TR?=M2jjRnNCVkeHUh?=
K-562NHXWWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LnTWlEPTB;OD64N|k2PyEQvF2=NYDJeIlTW0GQR1XS
SBC-1MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRThwOE[2OFUh|ryPNIGzPYNUSU6JRWK=
ES4MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjNTWM2OD16Lki2PFg1KM7:TR?=NESw[JVUSU6JRWK=
MS-1NHfRVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHm3VWRKSzVyPUiuPFc2OTdizszNNIL4[FdUSU6JRWK=
RKOM2TpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVWxVGlLUUN3ME24Mlg6ODV5IN88US=>M2Pj[nNCVkeHUh?=
NCI-H1693NGT4OppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;uXJI4UUN3ME24MlkzOTdizszNNGLXSFRUSU6JRWK=
SW954MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rac2lEPTB;OD65Olk4QCEQvF2=NXLURVJuW0GQR1XS
SK-UT-1M1vROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7idHl1UUN3ME24Mlk4Pjh|IN88US=>MYTTRW5ITVJ?
T98GNYXuZ24zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHhTWM2OD16Lkm5PFQ3KM7:TR?=MYrTRW5ITVJ?
NCI-H2126NYWzdJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\UTWM2OD17LkCwPFI3KM7:TR?=MlTSV2FPT0WU
TE-12MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTlwMEOzOlch|ryPM{TWUHNCVkeHUh?=
DK-MGM4XvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIK0UmpKSzVyPUmuNlEyQTFizszNNFHXbJBUSU6JRWK=
MEG-01MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPJTWM2OD17LkK0PVMyKM7:TR?=MYLTRW5ITVJ?
HCC1937M4\BVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTlwMkmwPVEh|ryPMkS3V2FPT0WU
MKN45NYLnepRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;Y[GlEPTB;OT60OVA3PSEQvF2=NVTEc5lGW0GQR1XS
NCI-H1792MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTYTWM2OD17LkS1NlE6KM7:TR?=MXzTRW5ITVJ?
SW1417MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M134O2lEPTB;OT61Olg{PyEQvF2=MYXTRW5ITVJ?
639-VM2ntcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTlwNkSzPFgh|ryPNUXrcpdXW0GQR1XS
P30-OHKM2r4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnINXBKSzVyPUmuOlU{OTZizszNNGjicnRUSU6JRWK=
YKG-1NH7uOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTlwN{WwN|Mh|ryPMoXLV2FPT0WU
KGNMle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWOyU5pLUUN3ME25Mlg{Pzl3IN88US=>NYPGcFM{W0GQR1XS
MSTO-211HMlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTlwOUW1Nlkh|ryPNEfL[mZUSU6JRWK=
NCI-H1573M2HMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTFyLkG1O|Qh|ryPNHLUTJZUSU6JRWK=
NCI-H720NEXQWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXHrPXU6UUN3ME2xNE4yQTh7IN88US=>NWrHfXI4W0GQR1XS
KARPAS-45NVGzd2hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTFyLkK3PVUh|ryPNX7rfJZUW0GQR1XS
MDA-MB-175-VIIMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{mz[WlEPTB;MUCuOFgh|ryPMXfTRW5ITVJ?
SK-NEP-1M2rFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTFyLkS5PFEh|ryPM{jkT3NCVkeHUh?=
MKN28MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2S1eWlEPTB;MUCuOVE5KM7:TR?=NIXGSnJUSU6JRWK=
KYSE-520M4jF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfoUJlKSzVyPUGwMlUzKM7:TR?=M{fE[HNCVkeHUh?=
KE-37NECySGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzPTWM2OD1zMD61NlczKM7:TR?=NHfpXpNUSU6JRWK=
VA-ES-BJNHPiPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7tcndKSzVyPUGwMlU3PyEQvF2=MoO0V2FPT0WU
CCRF-CEMNXnEeoNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVviUXplUUN3ME2xNE42Pjh2IN88US=>MVzTRW5ITVJ?
GMS-10M4D5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnm1TWM2OD1zMD62NFk1KM7:TR?=Ml3oV2FPT0WU
NCI-H1623M4nSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTFyLk[zO|kh|ryPMV\TRW5ITVJ?
NEC8NXLQeFRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml[3TWM2OD1zMD63O|c{KM7:TR?=NHX2dFZUSU6JRWK=
MOLT-16NXzZNpZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\qOmlEPTB;MUCuPFEyOyEQvF2=MV3TRW5ITVJ?
DJM-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTmTWM2OD1zMT6wN|c6KM7:TR?=MYnTRW5ITVJ?
U251NFfxTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;OOlJKSzVyPUGxMlA1OiEQvF2=NH;lUWZUSU6JRWK=
SBC-5M3jBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDETFZKSzVyPUGxMlE1PjdizszNMUXTRW5ITVJ?
SW756NXfMUVRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\4TWszUUN3ME2xNU4zOTV2IN88US=>NUPleohSW0GQR1XS
KS-1NHXPVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LMcGlEPTB;MUGuNlYyQSEQvF2=NXjwUlJkW0GQR1XS
SF295MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHBTWM2OD1zMT6zNVA1KM7:TR?=Mk\TV2FPT0WU
YH-13MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTJSopyUUN3ME2xNU4{OjZ5IN88US=>M{HyfXNCVkeHUh?=
SW837MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTFzLkO1NFYh|ryPNXfpT3N[W0GQR1XS
KYSE-450M{DLNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\yXGlEPTB;MUGuOFA2PyEQvF2=M{\6fXNCVkeHUh?=
KYSE-180NFToOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17CcmlEPTB;MUGuOFgzKM7:TR?=MnfRV2FPT0WU
S-117NI\kS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzpUmtzUUN3ME2xNU41QDl4IN88US=>M1jPWnNCVkeHUh?=
KOSC-2MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDiZ5ZKSzVyPUGxMlYzOjJizszNMorFV2FPT0WU
KYSE-270M1raUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jrXmlEPTB;MUGuPFc1PSEQvF2=MlniV2FPT0WU
D-336MGNXK0UmkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHLeIU5UUN3ME2xNU46ODd3IN88US=>NYLSc|JqW0GQR1XS
KALS-1M{\3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnIWZlKSzVyPUGyMlAxOTZizszNMlOzV2FPT0WU
LB373-MEL-DNHvMTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWqzNHZbUUN3ME2xNk4xPTN|IN88US=>NEjq[phUSU6JRWK=
HLEMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTF{LkC1PFUh|ryPNYP0UFBpW0GQR1XS
SJSA-1MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTF{LkC3N|Uh|ryPNVz5UpYyW0GQR1XS
SW1990MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTF{LkC5NVEh|ryPNUPKeWk3W0GQR1XS
NOS-1NEDDNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTF{LkGzOVIh|ryPM{jtPHNCVkeHUh?=
GI-ME-NMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHT2UINKSzVyPUGyMlIyPjNizszNM3;Kd3NCVkeHUh?=
NCI-H1703M{Drbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTF{LkK2NVYh|ryPMVnTRW5ITVJ?
ES7NX7OUpRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NESyOGpKSzVyPUGyMlI4OjRizszNMnHtV2FPT0WU
KYSE-510NUSxUYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTF{LkWwO|kh|ryPM3Lkd3NCVkeHUh?=
BHYMkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPo[phDUUN3ME2xNk42OzB5IN88US=>MWDTRW5ITVJ?
TCCSUPM{LJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTF{LkW3OVch|ryPNWPLOGh[W0GQR1XS
HSC-2MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfrcnlbUUN3ME2xNk42QTl4IN88US=>M162TnNCVkeHUh?=
BENNGj4T3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfid5RqUUN3ME2xNk43OTR|IN88US=>NF2ySGFUSU6JRWK=
769-PNIPGb|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPLcY9GUUN3ME2xNk44QTJ2IN88US=>NVnhSWpkW0GQR1XS
HTMnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mme2TWM2OD1zMj64N|Q3KM7:TR?=M1HoSHNCVkeHUh?=
LXF-289M1LZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIS2[5pKSzVyPUGyMlk2OzFizszNM3TUXHNCVkeHUh?=
OVCAR-3NHOydlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;qVWVNUUN3ME2xNk46PTZ5IN88US=>MoLhV2FPT0WU
ATN-1MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTF|LkCxPFQh|ryPMV7TRW5ITVJ?
8-MG-BAMlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTF|LkC0OVUh|ryPM4HYe3NCVkeHUh?=
SW13NF6wclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TRfmlEPTB;MUOuNVE3PSEQvF2=MXzTRW5ITVJ?
NCI-H1092NHnwfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\mTGlEPTB;MUOuNVYzKM7:TR?=NUT0eoJXW0GQR1XS
OAW-42NEDEZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnCOXJKSzVyPUGzMlE6OzdizszNMYrTRW5ITVJ?
NCI-H2452NFe5ZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Dib2lEPTB;MUOuNlE4PSEQvF2=MVHTRW5ITVJ?
CAPAN-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvjU21KSzVyPUGzMlU2OTRizszNMmXLV2FPT0WU
NCI-H2009M133U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTF|LkW5NVkh|ryPNHuwWIdUSU6JRWK=
SF268M4rPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XaU2lEPTB;MUOuOlMzPiEQvF2=M2fkRXNCVkeHUh?=
GCIYNWLNeINpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\URZNyUUN3ME2xN{43QTJ5IN88US=>MonDV2FPT0WU
OS-RC-2MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLjTWM2OD1zMz65OVAyKM7:TR?=MXTTRW5ITVJ?
GCTMm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTF|Lkm2PVch|ryPMX7TRW5ITVJ?
NB17MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTF2LkC4OUDPxE1?NYnZdox1W0GQR1XS
NCI-H2030NVTZfVRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3v0UmlEPTB;MUSuNVQ3PSEQvF2=M3;XW3NCVkeHUh?=
HC-1NFriZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH21S2lKSzVyPUG0MlIxQDdizszNMX3TRW5ITVJ?
QIMR-WILNInrTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTF2LkO0NVIh|ryPMYXTRW5ITVJ?
Capan-2M4HOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTF2LkO3NVQh|ryPNYjYfXBLW0GQR1XS
BALL-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvzTWM2OD1zND60OlY2KM7:TR?=MoXJV2FPT0WU
LS-1034NHftTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLST2RWUUN3ME2xOE43OTV{IN88US=>NF[0SopUSU6JRWK=
U-118-MGM1mwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTF2Lk[zNUDPxE1?MojvV2FPT0WU
NCI-H630NUTuZox6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTF2Lk[1Olgh|ryPMVrTRW5ITVJ?
OVCAR-8MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXYfJpKSzVyPUG0MlczODFizszNMlHhV2FPT0WU
NCI-H2347NIDScYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHOU3pKSzVyPUG0MlgzOyEQvF2=MorzV2FPT0WU
BT-549NITlSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTF2LkiyPFQh|ryPNXv3TFJoW0GQR1XS
LB831-BLCM2jIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTF2Lki5N|Qh|ryPM{XJVHNCVkeHUh?=
NCI-H661M{TvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLpTWM2OD1zND65OVkh|ryPNYXGcFR4W0GQR1XS
MKN7MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nwZmlEPTB;MUWuNFA6OyEQvF2=MkfnV2FPT0WU
U-87-MGNUnIXIpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;vfGlEPTB;MUWuNFg6PyEQvF2=MljZV2FPT0WU
OVCAR-4MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmC3TWM2OD1zNT6xOFI1KM7:TR?=MUnTRW5ITVJ?
OE33Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXYV|VNUUN3ME2xOU4yPzFzIN88US=>NFHiOFlUSU6JRWK=
EC-GI-10NXzNUXNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTF3LkKzOVch|ryPMki3V2FPT0WU
AM-38M1XvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnM[JFkUUN3ME2xOU4zPzF5IN88US=>MVPTRW5ITVJ?
NCI-H1563MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTF3LkO0PUDPxE1?NU\BTpl4W0GQR1XS
SCC-4MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVWyenFVUUN3ME2xOU41OTB|IN88US=>MULTRW5ITVJ?
Detroit562NWHTOVVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzBTWM2OD1zNT60OVQ4KM7:TR?=MmjaV2FPT0WU
PC-14MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTF3LkS4OlYh|ryPM2XZcXNCVkeHUh?=
ES3MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHy1dmJKSzVyPUG1MlU{PiEQvF2=NHrtZmxUSU6JRWK=
OCI-AML2NVeyV2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTF3Lke2NVQh|ryPNFHYbXBUSU6JRWK=
LU-134-ANVX0TWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorSTWM2OD1zNT65NFE5KM7:TR?=NUXTbmE1W0GQR1XS
SASNHvtOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTF3LkmzO|Mh|ryPMmrJV2FPT0WU
TGBC11TKBMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVqwNW5XUUN3ME2xOU46PDF2IN88US=>NVfHemlmW0GQR1XS
HOP-62M3W1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfNbW85UUN3ME2xOU46PTl5IN88US=>M1y0UHNCVkeHUh?=
G-401M1:wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\QO3hxUUN3ME2xOU46PjR7IN88US=>NUjZNIIyW0GQR1XS
NCI-H28NEPrPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTF4LkC4OVYh|ryPM1qyeXNCVkeHUh?=
A204NEfJXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\GSZlpUUN3ME2xOk4zODB4IN88US=>MUXTRW5ITVJ?
NCI-H1299M17jSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTF4LkKyPVEh|ryPMkf3V2FPT0WU
VMRC-RCZM1LMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXv2ZZFwUUN3ME2xOk4zPTl{IN88US=>NIfxeW9USU6JRWK=
BxPC-3M37VbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDHO5dKSzVyPUG2MlI5PTZizszNM2DRe3NCVkeHUh?=
NCI-H2228M3fXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHmflhKSzVyPUG2MlUyPThizszNMUjTRW5ITVJ?
NCI-H23M2HM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTF4Lk[wO|gh|ryPM{TY[3NCVkeHUh?=
NKM-1M{TQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LzXGlEPTB;MUeuNFE5QSEQvF2=MVvTRW5ITVJ?
KYSE-70MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nMfGlEPTB;MUeuNlg6KM7:TR?=MULTRW5ITVJ?
BB49-HNCMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\SPZNKSzVyPUG3MlU3QDZizszNM1;Eb3NCVkeHUh?=
SCC-15NHXsbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVu4XFY6UUN3ME2xO{45PDd|IN88US=>NH;4SmpUSU6JRWK=
D-247MGNV3USI9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\kTnpKSzVyPUG3MlkzPDdizszNNYrD[nVLW0GQR1XS
BB30-HNCNX74elN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTF6LkCzNVgh|ryPM3i5UHNCVkeHUh?=
CAL-85-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzjUolkUUN3ME2xPE4yQDB7IN88US=>MYHTRW5ITVJ?
HT-3NFX6fFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTF6LkO5O|ch|ryPM2nPbHNCVkeHUh?=
KYSE-410NInEb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPSXnBKSzVyPUG4MlQ2PzdizszNMlnLV2FPT0WU
SW982MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDMSVBKSzVyPUG4MlU3PDlizszNMlXFV2FPT0WU
SW962MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXn3NlRwUUN3ME2xPE42PzB{IN88US=>NWrae5A4W0GQR1XS
Ramos-2G6-4C10MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnj0TWM2OD1zOD61PVI4KM7:TR?=M{TtfXNCVkeHUh?=
OC-314Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PrZ2lEPTB;MUiuO|M5PCEQvF2=NIK2fXFUSU6JRWK=
LS-123M{D2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTF6Lke5NFEh|ryPNYT4ZoMzW0GQR1XS
D-502MGMmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTF6LkixN|kh|ryPMWPTRW5ITVJ?
RO82-W-1MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TueWlEPTB;MUiuPFI5QCEQvF2=MWXTRW5ITVJ?
HuO9MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTze21oUUN3ME2xPU4yOzd7IN88US=>NHq3SoxUSU6JRWK=
ETK-1M3PMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7MTWM2OD1zOT6xPFI4KM7:TR?=M4Xsc3NCVkeHUh?=
SNU-387NIjCVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTF7LkG4PFkh|ryPM4C5VnNCVkeHUh?=
SW1573NYr0TYdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYD2cpRmUUN3ME2xPU4yQTZ7IN88US=>M3rqSHNCVkeHUh?=
NTERA-S-cl-D1NE\o[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmi0TWM2OD1zOT6yNFA4KM7:TR?=M2HaU3NCVkeHUh?=
SF126MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1y5c2lEPTB;MUmuN|UxOiEQvF2=NY\hO4lOW0GQR1XS
Calu-3NYDLWIhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTF7LkSyN|ch|ryPNGrBOnVUSU6JRWK=
NCI-H1048Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPpdndKSzVyPUKwMlMzPjZizszNMUnTRW5ITVJ?
NCI-H226M2n4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NET3RppKSzVyPUKwMlQ{QTlizszNNF;OTHNUSU6JRWK=
FTC-133MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTJyLkS3NFMh|ryPM2DkVXNCVkeHUh?=
SF539MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXVe5RKSzVyPUKwMlUyPzJizszNNUjkPFdqW0GQR1XS
TE-6NUi2eHNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTJyLkiwOlch|ryPMVXTRW5ITVJ?
UMC-11M{PM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPoUnR[UUN3ME2yNE46OTZ2IN88US=>MlPKV2FPT0WU
BeckerMn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTJzLkGxNVgh|ryPM4T0SXNCVkeHUh?=
KP-4NWDGcotzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3v5fWlEPTB;MkGuNVE6PiEQvF2=M2njWHNCVkeHUh?=
ChaGo-K-1MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\oXGlEPTB;MkGuN|YzPyEQvF2=NEDnR21USU6JRWK=
CFPAC-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrpT3RKSzVyPUKxMlM5PThizszNNF;TT|RUSU6JRWK=
A498MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYq2RYo2UUN3ME2yNU42OzF{IN88US=>MXnTRW5ITVJ?
NCI-H1755Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTJzLk[3OFEh|ryPM1nJ[nNCVkeHUh?=
TI-73MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXKTWM2OD1{Mj6zNlgh|ryPNYG2UG1tW0GQR1XS
NCI-H441M1LwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTJ{LkW2PFkh|ryPNGH5cVZUSU6JRWK=
CaR-1M4TXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PmbGlEPTB;MkOuNFIyOyEQvF2=MVLTRW5ITVJ?
HCC1806NYDiTWt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHaTWM2OD1{Mz6wOVg{KM7:TR?=NX64THdiW0GQR1XS
SNU-449NV3WPFFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIH0S3JKSzVyPUKzMlMzQSEQvF2=NIfhOZZUSU6JRWK=
EKVXM4\5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rFcWlEPTB;MkOuN|kxQSEQvF2=NGHaclNUSU6JRWK=
DMS-114M3zmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHHZndSUUN3ME2yN{42PzZ3IN88US=>M3LMNXNCVkeHUh?=
A704MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTJ|Lk[xNFMh|ryPMVrTRW5ITVJ?
LC-2-adM4nifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLjcZRKSzVyPUKzMlYyPDdizszNNFricJhUSU6JRWK=
VM-CUB-1NWLJb5UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn[yTWM2OD1{Mz63N|QyKM7:TR?=NXG2Vo9OW0GQR1XS
PC-3MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LabmlEPTB;MkSuNFUzPiEQvF2=NGT6TGtUSU6JRWK=
HELNEjCWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHJXlFDUUN3ME2yOE4xQDZ3IN88US=>MoTNV2FPT0WU
ABC-1NF3CUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{naW2lEPTB;MkSuNlczQSEQvF2=M1ja[XNCVkeHUh?=
COLO-680NNYe5ZpN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXL0R2JrUUN3ME2yOE41PzZ2IN88US=>MnvpV2FPT0WU
MZ1-PCMnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1znR2lEPTB;MkSuOlg4KM7:TR?=NWC1XYdqW0GQR1XS
NCI-H69NI\rb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vxe2lEPTB;MkSuO|M2PCEQvF2=NV;TN|RxW0GQR1XS
TE-1NF;3NnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjIfoZKSzVyPUK1MlA1QTlizszNNUHaflRWW0GQR1XS
EW-3M1yweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13pfWlEPTB;MkWuNVE{KM7:TR?=NWPBUXFEW0GQR1XS
PANC-08-13MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHaTWM2OD1{NT64NVA{KM7:TR?=MnTtV2FPT0WU
NMC-G1MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPRTWM2OD1{Nj6wNFg5KM7:TR?=M{[2e3NCVkeHUh?=
BT-20NVm3OlZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfIS|FKSzVyPUK2MlQ2PDNizszNMU\TRW5ITVJ?
TGBC24TKBMn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXTTWM2OD1{Nj63N|MyKM7:TR?=NXHWVo53W0GQR1XS
TE-11MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\OV2NsUUN3ME2yOk46QDl3IN88US=>M3TxT3NCVkeHUh?=
ESS-1NHjFcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7hOG5KSzVyPUK3MlMzOTZizszNMYDTRW5ITVJ?
JVM-3MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTJ5Lk[0O|Uh|ryPMofsV2FPT0WU
C3AM3nHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTJ5Lki0PVYh|ryPMW\TRW5ITVJ?
MDA-MB-157M1\vNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3Gc49nUUN3ME2yO{45PzV|IN88US=>NUHTdZJOW0GQR1XS
KLEM2e4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnvPYJUUUN3ME2yPE4yODV6IN88US=>M4L4dHNCVkeHUh?=
ES1NI\xc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnO2TWM2OD1{OD6xPFM5KM7:TR?=NFzMdotUSU6JRWK=
CAL-120MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGT3NXFKSzVyPUK4MlM6QTlizszNNYDDNoRjW0GQR1XS
NCI-N87M1XFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmO3TWM2OD1{OD61NVA2KM7:TR?=MkG1V2FPT0WU
RPMI-8226M{fEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPjSFBKSzVyPUK5MlE5PDNizszNMXLTRW5ITVJ?
COR-L88MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDnc2ZqUUN3ME2yPU4zPDF7IN88US=>NFjF[3BUSU6JRWK=
UACC-893NHvVRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTJ7LkOxN|ch|ryPMoj0V2FPT0WU
C8166M33GdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoX0TWM2OD1{OT65PVk3KM7:TR?=NFTRc3NUSU6JRWK=
J82NELyN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTNyLkixOFch|ryPMkDPV2FPT0WU
PFSK-1NEm2e2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLleVFiUUN3ME2zNU4xPjV7IN88US=>NIC4PFZUSU6JRWK=
COLO-684NI\1V5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTNzLkSzO|Qh|ryPNGn5VFdUSU6JRWK=
CAL-72NXzOU4VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml22TWM2OD1|MT61O|I6KM7:TR?=NGKyTJFUSU6JRWK=
SNB75M{D4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3TVZBQUUN3ME2zNU45QTdizszNM1TVUHNCVkeHUh?=
MDA-MB-415M1XoUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{O3fWlEPTB;M{GuPVc3OiEQvF2=MoPNV2FPT0WU
SiHaM1zRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7nXJJKSzVyPUOyMlQ4OTFizszNNHi2fINUSU6JRWK=
NCI-H1648NHH5OmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\yR4NKSzVyPUOyMlk{PDVizszNNVHBXW9SW0GQR1XS
EFO-21NXHsUIFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LDemlEPTB;M{OuNFA2KM7:TR?=NX\hUmhFW0GQR1XS
HCC38M3\ETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17TVWlEPTB;M{OuN|g1OSEQvF2=NIPXelBUSU6JRWK=
IA-LMM{CwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTwTWM2OD1|Mz63PFg6KM7:TR?=NIjYVXpUSU6JRWK=
CTV-1NHXMcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTN|Lkm3PFYh|ryPMWTTRW5ITVJ?
NCI-H446MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrITWM2OD1|ND6yOlg6KM7:TR?=NGTtW4tUSU6JRWK=
IST-SL1MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTN2Lke0NFgh|ryPM4\HdnNCVkeHUh?=
EW-22MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTN2Lke3OVkh|ryPMVLTRW5ITVJ?
JEG-3NX3KNlI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTN4LkG3OlYh|ryPM4Ty[3NCVkeHUh?=
LU-65Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\mVWlEPTB;M{[uNlk5PSEQvF2=NEj4ephUSU6JRWK=
NCI-H596NVrqRnBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1THVWlEPTB;M{[uPVU6OSEQvF2=MlnBV2FPT0WU
KNS-81-FDNYDzXFZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUm2eFF4UUN3ME2zO{4yPDVizszNMnT4V2FPT0WU
NCI-H1793MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXK2UplzUUN3ME2zO{44ODh4IN88US=>NXj3c3J4W0GQR1XS
NCI-H460MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mle0TWM2OD1|OD6wPFc{KM7:TR?=MYXTRW5ITVJ?
MPP-89NWHlSmlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrRbJBrUUN3ME2zPU42QDh4IN88US=>NUPhbHVPW0GQR1XS
D-542MGMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTN7Lki0N|Yh|ryPNIG4OJNUSU6JRWK=
JARNGLjUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorlTWM2OD12MD60O|A2KM7:TR?=NEGzUpZUSU6JRWK=
NCI-H209NUHxR|BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjmTWM2OD12MD62O|ch|ryPMWPTRW5ITVJ?
G-402Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLOTWM2OD12MT6zPVk{KM7:TR?=NWnpWHdXW0GQR1XS
IST-MES1NHS0PXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PaTGlEPTB;NEKuNVk{PSEQvF2=MnnnV2FPT0WU
DaoyM{n6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHi5OnpKSzVyPUSyMlU1PzFizszNMmX0V2FPT0WU
EW-11NIizTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTR|LkGyNVEh|ryPNYqwb5lNW0GQR1XS
Saos-2NIfKZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTR|LkG1N|ch|ryPNX;Yd5JLW0GQR1XS
no-10MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHj4VVlKSzVyPUSzMlE4ODJizszNMnfnV2FPT0WU
HCC1395MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH:ySXZKSzVyPUSzMlQ3PDRizszNNYSzdmFWW0GQR1XS
HCE-4MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mom2TWM2OD12Mz63OlY1KM7:TR?=MoHvV2FPT0WU
EW-1NVTJNoxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLYUI1SUUN3ME20N{45ODR7IN88US=>MXzTRW5ITVJ?
OCUB-MMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mne4TWM2OD12ND6zOlM5KM7:TR?=M2fsd3NCVkeHUh?=
IGR-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3DTWM2OD12ND60NVE2KM7:TR?=NWTPWGlNW0GQR1XS
NCI-H1838MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInqUWhKSzVyPUS0MlQ{PDlizszNNITvdHdUSU6JRWK=
NCI-H2405Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rtSGlEPTB;NESuOVM1KM7:TR?=MoPBV2FPT0WU
GB-1NHrRbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PyUWlEPTB;NESuO|Q3OyEQvF2=MlvwV2FPT0WU
MG-63NGT1dnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXmTWM2OD12Nj6wOlk3KM7:TR?=MkGyV2FPT0WU
KP-N-YNNGDQSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzifZJKUUN3ME20Ok41Pjd7IN88US=>NYjjZXpoW0GQR1XS
no-11MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\rTWM2OD12Nz6wNlQ1KM7:TR?=NEnQNFJUSU6JRWK=
SW948NEHHdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTR5LkOzO|ch|ryPNXvCcm05W0GQR1XS
CAMA-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHtdml2UUN3ME20O{4{PDN6IN88US=>M3\Q[HNCVkeHUh?=
HCC1187M13ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLUZ2I{UUN3ME20O{42OSEQvF2=NIjGfXZUSU6JRWK=
D-392MGMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWG2e4g6UUN3ME20O{43PTF4IN88US=>MX3TRW5ITVJ?
647-VNWW0SpBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LyeWlEPTB;NEmuN|QyPCEQvF2=MVvTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]
Features First MEK inhibitor to begin clinical development.

Protocol(Only for Reference)

Kinase Assay:

[2]

MEK1 Assay MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.

Cell Assay:

[1]

Cell lines Colon 26 carcinoma cells
Concentrations 0.1-10 μM
Incubation Time 24 hours
Method

Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.

Animal Study:

[3]

Animal Models PTC cells in athymic mice
Formulation Cremophor EL–95% ethanol (50:50) and dilutes with water
Dosages 150 mg/kg
Administration Orally twice daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Sebolt-Leopold JS, et al. Nat Med, 1999, 5(7), 810-816.

[2] Davies SP, et al. Biochem J, 2000, 135(1), 95-105.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Insti  ...more University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Chemical Information

Download PD184352 (CI-1040) SDF
Molecular Weight (MW) 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related MEK Products

  • Cobimetinib (GDC-0973, RG7420)

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM. Phase 3.

  • BI-847325

    BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.

  • GDC-0623

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.

  • Trametinib (GSK1120212)

    Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

    Features:More potent than PD0325901 or AZD6244.

  • PD0325901

    PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

  • Selumetinib (AZD6244)

    Selumetinib (AZD6244) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM in cell-free assays, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

    Features:First MEK inhibitor being tested in Phase II clinical trials.

  • U0126-EtOH

    U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

    Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.

  • PD98059

    PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

    Features:Does not inhibit c-Raf phosphorylated MEK1.

  • Binimetinib (MEK162, ARRY-162, ARRY-438162)

    Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.

  • Refametinib (RDEA119, Bay 86-9766)

    Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Recently Viewed Items

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us